Current report 21/2021 – entering the authorized capital and the increase in the Company’s share capital into the National Court Register (KRS)

Current reports May 6, 2021

Management Board of Celon Pharma S.A. The “Company” informs that on May 5, 2021, it was entered into the register of the Regional Court for the capital city of Warsaw in Warsaw, 14th Economic Division of the National Court Register, entry in Section No. 8 of the KRS:

Adoption of a resolution on amending the Company's Articles of Association and authorising the Company's Management Board to increase the share capital within the authorized capital, with the Management Board's possibility to exclude the pre-emptive rights issued within the authorized capital, in whole or in part, with the consent of the Supervisory Board. “Resolution No. 4/2021”);

- an increase of PLN 200 000 of the share capital, in light of the adoption of resolution No. 7/2021 by the Company’s Extraordinary General Meeting on February 16, 2021, in order to implement Motivational Programs for the Members of the Board and other people of key significance to the Company, A-series subscription warrants, excluding the pre-emptive right of the existing shareholders, entitling to subscribe C-series shares and to increase the share capital by issuing C-series shares, excluding pre-emptive rights of the existing shareholders, and all the relevant amendments to the Company’s Articles of Association.

The Company’s Management Board advises that the content of the resolutions adopted by the Company’s Extraordinary General Meeting on February 16, 2021 was released to the public in the form of current report No. 9/2021, and information about the registration of the relevant amendments to the Company’s Articles of Association was released in current report No. 20/2021.